Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Floats Prefectural Bodies for Regional Formularies, LLP Copay Hike Gains Traction: LDP-Ishin Talks
The Liberal Democratic Party (LDP) and the Japan Innovation Party (Nippon Ishin) continued their bilateral discussions on social security reform on November 26, with the health ministry proposing that every prefecture set up a forum in FY2026 to develop regional…
To read the full story
Related Article
- MHLW Eyes Govt-Led Ingredient Lists for Regional Formularies: LDP Briefing
December 9, 2025
- LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
November 25, 2025
- Ishin Presses Govt to Commit to OTC-Like Drug Reform by FY2026
November 13, 2025
REGULATORY
- New Chuikyo Payer Rep Wary of Blanket Inflation Adjustment for Reimbursement
June 17, 2026
- CEA Review Group Discusses Evidence for Additional Usefulness
June 17, 2026
- Japan Sets 6-Billion-Yen Donation Target for Drug Discovery Fund
June 17, 2026
- Drug Makers Back Patent Protection for AI-Generated Inventions: JPO
June 17, 2026
- LDP Panel Calls for Action on Women’s Health Issues in Policy Proposals
June 17, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…